$14.30
4.22% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Stock price

$14.30
+2.59 22.12% 1M
+4.88 51.80% 6M
+11.07 342.72% YTD
+11.28 373.51% 1Y
-5.92 29.28% 3Y
-7.50 34.40% 5Y
-7.50 34.40% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.63 4.22%
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Key metrics

Market capitalization $1.67b
Enterprise Value $1.55b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.18
P/S ratio (TTM) P/S ratio 12.07
P/B ratio (TTM) P/B ratio 10.68
Revenue growth (TTM) Revenue growth 182.84%
Revenue (TTM) Revenue $138.71m
EBIT (operating result TTM) EBIT $-181.93m
Free Cash Flow (TTM) Free Cash Flow $-167.80m
Cash position $331.18m
EPS (TTM) EPS $-1.79
P/E forward negative
P/S forward 9.29
EV/Sales forward 8.61
Short interest 24.87%
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
139 139
183% 183%
100%
- Direct Costs 15 15
271% 271%
11%
124 124
175% 175%
89%
- Selling and Administrative Expenses 218 218
27% 27%
157%
- Research and Development Expense 86 86
29% 29%
62%
-179 -179
27% 27%
-129%
- Depreciation and Amortization 2.53 2.53
53% 53%
2%
EBIT (Operating Income) EBIT -182 -182
27% 27%
-131%
Net Profit -196 -196
27% 27%
-141%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
22 days ago
WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation C...
Positive
Seeking Alpha
about one month ago
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower e...
Neutral
Seeking Alpha
about 2 months ago
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan...
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 296
Founded 2016
Website www.arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today